We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Bespak | LSE:BPK | London | Ordinary Share | GB0000946276 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 667.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Bespak PLC 24 April 2006 For immediate release 24 April 2006 Bespak plc ('the Company') Bespak and Bang & Olufsen Medicom Collaborate on Next Generation Inhaler New Inhaler features integrated dose counter and easy-to-operate mechanism Bespak plc (LSE: BPK), a leader in specialty medical devices, and Bang & Olufsen Medicom, an innovative drug delivery device solutions provider, are pleased to jointly announce today that they have entered into an exclusive partnership to co-develop and co-market a single increment dose-counting inhaler. This will be the first integrated dose-counting device to feature an assisted firing mechanism which will aid patient use. The partnership has been formed to develop a next generation "press and breathe" inhaler which will be aimed at the expanding Asthma and COPD (Chronic Obstructive Pulmonary Disease) market. Bang & Olufsen's intellectual property in the area of design and development will be enhanced by Bespak's in-depth understanding of valve technologies and precision of dose delivery, both of which are essential to the development of any reliable dose-counting mechanism. The two companies will share responsibility for the development, manufacture and co-promotion of the device. The functionality of the device has been thoroughly validated and is ready for incorporation into a metered dose inhaler programme immediately. Bespak and Bang & Olufsen Medicom are currently seeking alliances with pharmaceutical companies interested in providing new inhaler solutions for patients. Mark Throdahl, Chief Executive Officer of Bespak, said: "Bang & Olufsen Medicom has a strong design based heritage and an insight into patient compliance. In particular, we think their dose-counting mechanism will bring a lot of value to the collaboration. Together, our joint forces enable us to bring the device to the market in high volumes within strict quality and design guidelines." Welcoming the news from Bang & Olufsen Medicom, Chief Executive Officer Henrik Kagenow, said: "We are excited it will be the first patient compliance device on the market with a dose counter that meets FDA requirements. We are delighted to work with Bespak, who are recognised leaders in the field of inhalation valves and bring a wealth of inhaler manufacturing expertise to the partnership." ENDS For further information please call: Bespak plc Mark Throdahl - Chief Executive +44 (0) 20 1908 552 600 Martin Hopcroft - Group Finance Director Buchanan Communications +44 (0) 20 7466 5000 Tim Thompson / Mark Court / Mary-Jane Johnson Notes for Editors: About Bespak plc Bespak, a leader in specialty medical devices, develops delivery systems for the pharmaceutical industry and disposable airway management products for critical care settings. Bespak's product range includes metered dose and dry powder inhalers, actuators, inflation valves, disposable face masks, breathing circuits and laryngeal tubes. The group, which has facilities in King's Lynn and Milton Keynes in the UK and Indianapolis and Kent, Ohio, in the US, is quoted on the Official List of the London Stock Exchange (LSE: BPK). For more information, please visit www.bespak.com. About Bang & Olufsen Medicom Bang & Olufsen Medicom is a leading expert in the design, development and supply of innovative drug delivery device solutions and sensor based technologies. The current product range includes; inhalers, tablet reminders and injection pens with a focus on patient compliance. Bang & Olufsen Medicom offers concept development, engineering and manufacturing services to clients with options to licence its intellectual property. For more information you can visit: http:// www.medicom.bang-olufsen.com Asthma and COPD The pMDI (pressurised Metered Dose Inhalers) market is believed to have a worldwide volume of 400 million units. Asthma is a chronic inflammation of the airways that is marked by continuous laboured breathing accompanied by wheezing, breathlessness, a sense of constriction in the chest and coughing or gasping attacks. Chronic obstructive pulmonary disease (COPD) is often, though not always, caused by smoking. COPD is a pulmonary disease that is characterized by chronic, typically irreversible airway obstruction resulting in a slowed rate of exhalation. The airflow limitation is associated with an abnormal inflammatory response of the lungs to noxious particles or gases. Patient compliance rates in Asthma and COPD are estimated to be in the region of 50%, a significant contributor to patient non compliance is said to be both forgetfulness and the lack of visibility on dose tracking. Image bank To download images of the Inhaler (Assist Actuated InhalerTM) please visit the Bang & Olufsen Medicom center: http://mediacenter.bang-olufsen.dk/MediaCenter/mc.nsf simply register the first time you visit. This information is provided by RNS The company news service from the London Stock Exchange END NRASEIFELSMSEFL
1 Year Bespak Chart |
1 Month Bespak Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions